Alnylam

@Alnylam

Alnylam is the world’s leading RNAi therapeutics company. We believe that patients living with life-threatening diseases deserve innovative new treatments.

Cambridge, MA
Vrijeme pridruživanja: kolovoz 2009.

Medijski sadržaj

  1. 15. sij

    We're to welcome our first Co-op class of the new decade! This outstanding group of 33 co-ops and legal externs represents , and . Learn more about career development at Alnylam here:

  2. 5. pro 2019.

    We’re thrilled to share that ONPATTRO (patisiran) was awarded “Best New Drug” honors at last evening’s in London. Not only was ONPATTRO our first commercial product but it was also the world’s first FDA and EMA-approved therapeutic.

  3. 22. stu 2019.

    On Tuesday evening in Amsterdam, we co-hosted a wonderful program of speakers & discussions about promoting in the industry in the and beyond. Thank you to all who made this important event possible!

    , , i još njih 5
  4. 22. stu 2019.

    Our 2019 R&D Day (our 10th!) is in full swing in NYC. We’re providing commercial and investigational program and platform updates. You can join via webcast here: or access the replay following the event.

  5. 21. stu 2019.

    Yesterday’s approval of GIVLAARI (givosiran) is a landmark event for Alnylam and the patient community and also represents significant progress for GalNAc-conjugate technology uniquely pioneered by Alnylam. Learn more:

  6. 14. stu 2019.

    Caring for a child diagnosed with a rare disease can be difficult, and parents often adapt to play multiple roles as the years go by. Natalie and Jared speak about raising their children, diagnosed with primary type 1 (PH1).

  7. 12. stu 2019.

    Our COO Yvonne Greenstreet, MBChB, MBA joined other leaders from , , and 's Center for Biomedical Innovation earlier today for an insightful panel "Resolving Pharma’s Pricing Conundrum: A New Prescription" at the Conference.

  8. 12. stu 2019.

    One week until a great event on honoring the legacy of pioneer Henri A. Termeer taking place on Nov 19 in Amsterdam. See the list of distinguished speakers and program below. We invite you to attend and register:

    , , i još njih 5
  9. 5. stu 2019.

    Challenge Accepted->CHALLENGE CONQUERED! On 11/1, our David Jones (holding flag on the right) summited Mt. Kilimanjaro, Africa's highest peak at 19,341' while raising money for the Int'l CML Foundation. Congrats David! You've made us quite !

  10. 28. lis 2019.

    Original works of art like this one submitted by patients and caregivers as part of our "Art of Living with hATTR " program were on display this past weekend at the ATTR-Wild Type and Hereditary (Familial) Amyloidosis Support Group Meeting in Chicago.

  11. 25. lis 2019.

    We were honored to be considered among an outstanding field of contenders at last night’s awards! It was an amazing evening with our team celebrating new therapies with true patient impact! Congrats to our friends at !

  12. 18. lis 2019.

    Exciting additional speakers have been added. See updated program below!

    Prikaži ovu nit
  13. 18. lis 2019.

    We're happy to confirm a great lineup of speakers for an event on honoring the legacy of pioneer Henri A. Termeer taking place on Nov 19 in Amsterdam. See program below. We invite you to attend and register here:

    , , i još njih 5
    Prikaži ovu nit
  14. 8. lis 2019.

    We’re very proud to share that we’ve won the 2019 Prix Galien Italy Orphan Drug Award. Congratulations to all of the other winners from today’s event, and all of this year’s nominees!

  15. 7. lis 2019.

    Alnylam Assist – our U.S. patient services program, is central to our commitment to patients and ensuring they have access to the medicines we make. Case managers like Jessica are inspired by the patients and families they support, and our mission to always put .

  16. 2. lis 2019.

    The next PH1 of a Kind video has arrived! Watch as Luuk and older brother Sem from The Netherlands talk about life with the PH1 (primary type 1), and Sem helps Luuk understand why he’s not alone and should feel hopeful. Co-developed w/

  17. 1. lis 2019.

    At the culmination of this year’s , we wore blue to show our support for those living with debilitating conditions like acute hepatic (AHP).

  18. 28. ruj 2019.

    Alnylam Assist provides patients in the U.S. prescribed our therapy with a broad range of services from answering questions about insurance coverage to financial support for eligible patients.

  19. 25. ruj 2019.

    We’re thrilled to share that we’ve won the Prix Galien Netherlands Pharmaceutical Award 2019. Congratulations to all of the other winners from last evening’s event, and all of this year’s nominees!

  20. 23. ruj 2019.

    Our case managers like Caileen provide U.S. patients prescribed our medicines with personal and personalized support to help them navigate the process of starting therapy. Alnylam Assist is a critical part of our commitment to ensuring patient access.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·